The FASEB Journal, Vol 2, 2385-2395, Copyright © 1988 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Role of tumor cell glycoproteins immunologically related to glycoproteins Ib and IIb/IIIa in tumor cell-platelet and tumor cell- matrix interactions

IM Grossi, JS Hatfield, LA Fitzgerald, M Newcombe, JD Taylor and KV Honn
Department of Radiation Oncology, Wayne State University, Detroit, Michigan 48202.

A panel of monoclonal and polyclonal antibodies raised against human platelet GpIb or the GpIIb/IIIa complex were used to detect immunologically related molecules on two cell lines derived from human solid tumors. Human cervical carcinoma (MS751) and human colon carcinoma (clone A) expressed molecules immunologically related to platelet GpIb and GpIIb/IIIa complex. These molecules were localized to their plasma membranes by immunofluorescence and immunocytochemistry. The immunologically related GpIb was evenly distributed on the tumor cell membrane with occasional areas of aggregates, whereas the immunologically related GpIIb/IIIa had a pronounced punctate distribution of aggregates in prefixed cells. When MS751 or clone A cells were pretreated with antibodies against platelet GpIb and/or the GpIIb/IIIa complex, their ability to induce platelet aggregation was significantly inhibited. In addition, when tumor cells were pretreated with antibodies against the platelet IIb/IIIa complex, adherence to fibronectin-coated plates was also significantly inhibited. These results suggest a role for these immunologically related tumor cell glycoproteins in tumor cell-host cell (i.e., platelet, endothelial cells) interactions, tumor cell interactions with components of the subendothelial matrix, and subsequent tumor metastasis.

This article has been cited by other articles:

				C. Medina, P. Jurasz, M. J. Santos-Martinez, S. S. Jeong, T. Mitsky, R. Chen, and M. W. Radomski Platelet Aggregation-Induced by Caco-2 Cells: Regulation by Matrix Metalloproteinase-2 and Adenosine Diphosphate J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 739 - 745. [Abstract] [Full Text] [PDF]

				S. M. Smorenburg and C. J. F. Van Noorden The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies Pharmacol. Rev., March 1, 2001; 53(1): 93 - 106. [Abstract] [Full Text] [PDF]

				L. Oleksowicz, N. Bhagwati, and M. DeLeon-Fernandez Deficient Activity of von Willebrand's Factor-cleaving Protease in Patients with Disseminated Malignancies Cancer Res., May 1, 1999; 59(9): 2244 - 2250. [Abstract] [Full Text] [PDF]

				B. Felding-Habermann, R. Habermann, E. Saldívar, and Z. M. Ruggeri Role of beta3 Integrins in Melanoma Cell Adhesion to Activated Platelets under Flow J. Biol. Chem., March 8, 1996; 271(10): 5892 - 5900. [Abstract] [Full Text] [PDF]

				J Timar, R Bazaz, V Kimler, M Haddad, D. Tang, D Robertson, J Tovari, J. Taylor, and K. Honn Immunomorphological characterization and effects of 12-(S)-HETE on a dynamic intracellular pool of the alpha IIb beta 3-integrin in melanoma cells J. Cell Sci., January 6, 1995; 108(6): 2175 - 2186. [Abstract] [PDF]